Skip to main content

Advertisement

Articles

Page 4 of 16

  1. Cholinesterase inhibitors and memantine have been approved for management of Alzheimer’s disease (AD), but there has been no consensus about the choice of various types and doses of drugs at different stages. ...

    Authors: Kai-Xin Dou, Meng-Shan Tan, Chen-Chen Tan, Xi-Peng Cao, Xiao-He Hou, Qi-Hao Guo, Lan Tan, Vincent Mok and Jin-Tai Yu

    Citation: Alzheimer's Research & Therapy 2018 10:126

    Content type: Research

    Published on:

  2. The experiences of biomarker-ineligible cognitively normal persons can inform trial conduct and the translation of preclinical Alzheimer’s disease (AD) into clinical practice.

    Authors: Joshua D. Grill, Chelsea G. Cox, Kristin Harkins and Jason Karlawish

    Citation: Alzheimer's Research & Therapy 2018 10:125

    Content type: Research

    Published on:

    The Letter to this article has been published in Alzheimer's Research & Therapy 2019 11:52

  3. Trimethylamine N-oxide (TMAO), a small molecule produced by the metaorganismal metabolism of dietary choline, has been implicated in human disease pathogenesis, including known risk factors for Alzheimer’s diseas...

    Authors: Nicholas M. Vogt, Kymberleigh A. Romano, Burcu F. Darst, Corinne D. Engelman, Sterling C. Johnson, Cynthia M. Carlsson, Sanjay Asthana, Kaj Blennow, Henrik Zetterberg, Barbara B. Bendlin and Federico E. Rey

    Citation: Alzheimer's Research & Therapy 2018 10:124

    Content type: Research

    Published on:

  4. Subjective cognitive decline (SCD) consists of self-perceived decline in cognition over time. The occurrence of specific additional features in SCD (so-called SCDplus) confers a higher risk of future cognitive...

    Authors: Gonzalo Sánchez-Benavides, Oriol Grau-Rivera, Marc Suárez-Calvet, Carolina Minguillon, Raffaele Cacciaglia, Nina Gramunt, Carles Falcon, Juan Domingo Gispert and José Luis Molinuevo

    Citation: Alzheimer's Research & Therapy 2018 10:123

    Content type: Research

    Published on:

  6. The quantification of amyloid-beta (Aβ) peptides in blood plasma as potential biomarkers of Alzheimer’s disease (AD) is hampered by very low Aβ concentrations and the presence of matrix components that may int...

    Authors: Hedieh Shahpasand-Kroner, Hans-W. Klafki, Chris Bauer, Johannes Schuchhardt, Melanie Hüttenrauch, Martina Stazi, Caroline Bouter, Oliver Wirths, Jonathan Vogelgsang and Jens Wiltfang

    Citation: Alzheimer's Research & Therapy 2018 10:121

    Content type: Research

    Published on:

  7. Upon publication of this article [1], it was brought to our attention that one of the 303 participants in the normative study should have been deleted from the database.

    Authors: Morris Freedman, Larry Leach, M. Carmela Tartaglia, Kathryn A. Stokes, Yael Goldberg, Robyn Spring, Nima Nourhaghighi, Tom Gee, Stephen C. Strother, Mohammad O. Alhaj, Michael Borrie, Sultan Darvesh, Alita Fernandez, Corinne E. Fischer, Jennifer Fogarty, Barry D. Greenberg…

    Citation: Alzheimer's Research & Therapy 2018 10:120

    Content type: Correction

    Published on:

    The original article was published in Alzheimer's Research & Therapy 2018 10:65

  8. Peripheral biomarkers that identify individuals at risk of developing Alzheimer’s disease (AD) or predicting high amyloid beta (Aβ) brain burden would be highly valuable. To facilitate clinical trials of disea...

    Authors: Itziar de Rojas, J. Romero, O. Rodríguez-Gomez, P. Pesini, A. Sanabria, A. Pérez-Cordon, C. Abdelnour, I. Hernández, M. Rosende-Roca, A. Mauleón, L. Vargas, M. Alegret, A. Espinosa, G. Ortega, S. Gil, M. Guitart…

    Citation: Alzheimer's Research & Therapy 2018 10:119

    Content type: Research

    Published on:

  9. Amyloid-β 1–42 (Aβ1–42) peptide is a well-established cerebrospinal fluid (CSF) biomarker for Alzheimer’s disease (AD). Reduced levels of Aβ1–42 are indicative of AD, but significant variation in the absolute con...

    Authors: Stephen P. Schauer, William R. Mylott Jr, Moucun Yuan, Rand G. Jenkins, W. Rodney Mathews, Lee A. Honigberg and Kristin R. Wildsmith

    Citation: Alzheimer's Research & Therapy 2018 10:118

    Content type: Research

    Published on:

  10. Anti-amyloid β (Aβ) immunotherapy represents a major area of drug development for Alzheimer’s disease (AD). However, Aβ peptide adopts multiple conformations and the pathological forms to be specifically targe...

    Authors: Laurent Pradier, Véronique Blanchard-Brégeon, Andrees Bohme, Thomas Debeir, Jean Menager, Patrick Benoit, Pascal Barneoud, Véronique Taupin, Philippe Bertrand, Philippe Dugay, Béatrice Cameron, Yi Shi, Souad Naimi, Marc Duchesne, Marie Gagnaire, Tim Weeden…

    Citation: Alzheimer's Research & Therapy 2018 10:117

    Content type: Research

    Published on:

  11. Globalization of clinical trials has important consequences for trial planning and interpretation. This study investigated heterogeneity in patient characteristics and outcomes among world regions in the globa...

    Authors: Jeffrey L. Cummings, Alireza Atri, Clive Ballard, Neli Boneva, Lutz Frölich, José Luis Molinuevo, Lars Lau Raket and Pierre N. Tariot

    Citation: Alzheimer's Research & Therapy 2018 10:116

    Content type: Research

    Published on:

  12. Alzheimer’s disease (AD) is the most well-known and most common type of age-related dementia. Amyloid deposition and hyperphosphorylation of tau protein are both pathological hallmarks of AD. Using a triple-tr...

    Authors: Roger N. Rosenberg, Min Fu and Doris Lambracht-Washington

    Citation: Alzheimer's Research & Therapy 2018 10:115

    Content type: Research

    Published on:

  13. Low haemoglobin is highly prevalent among the elderly and has been associated with dementia. However, the mechanisms underlying this association with cognitive dysfunction, either through cerebrovascular disea...

    Authors: Bryce Tan, Narayanaswamy Venketasubramanian, Henri Vrooman, Ching-Yu Cheng, Tien Yin Wong, Christopher Chen and Saima Hilal

    Citation: Alzheimer's Research & Therapy 2018 10:114

    Content type: Research

    Published on:

  14. Biomarkers that can track disease onset and progression in autosomal dominant Alzheimer’s disease (ADAD) are needed. We investigate whether serum neurofilament light (NfL) concentration is associated with clin...

    Authors: Raquel Sánchez-Valle, Amanda Heslegrave, Martha S. Foiani, Beatriz Bosch, Anna Antonell, Mircea Balasa, Albert Lladó, Henrik Zetterberg and Nick C. Fox

    Citation: Alzheimer's Research & Therapy 2018 10:113

    Content type: Research

    Published on:

  15. In Alzheimer’s disease (AD), pathological changes may arise up to 20 years before the onset of dementia. This pre-dementia window provides a unique opportunity for secondary prevention. However, exposing non-d...

    Authors: Mara ten Kate, Silvia Ingala, Adam J. Schwarz, Nick C. Fox, Gaël Chételat, Bart N. M. van Berckel, Michael Ewers, Christopher Foley, Juan Domingo Gispert, Derek Hill, Michael C. Irizarry, Adriaan A. Lammertsma, José Luis Molinuevo, Craig Ritchie, Philip Scheltens, Mark E. Schmidt…

    Citation: Alzheimer's Research & Therapy 2018 10:112

    Content type: Research

    Published on:

  16. Most previous studies on dementia and injuries have focused on a particular type of injury, and few studies have investigated overall injury in people with dementia. In this study, we investigated the risk fac...

    Authors: Ruey Chen, Wu-Chien Chien, Ching-Chiu Kao, Chi-Hsiang Chung, Doresses Liu, Huei-Ling Chiu and Kuei-Ru Chou

    Citation: Alzheimer's Research & Therapy 2018 10:111

    Content type: Research

    Published on:

  17. Variability in biological parameters has been reported to be associated with adverse health outcomes. We aimed to investigate the composite effect of the visit-to-visit variability in blood pressure, glucose, ...

    Authors: Seung-Hwan Lee, Kyungdo Han, Hanna Cho, Yong-Moon Park, Hyuk-Sang Kwon, Gunseog Kang, Kun-Ho Yoon and Mee Kyoung Kim

    Citation: Alzheimer's Research & Therapy 2018 10:110

    Content type: Research

    Published on:

  18. Cerebrovascular pathology, quantified by white matter lesions (WML), is known to affect cognition in aging, and is associated with an increased risk of dementia. The present study aimed to investigate whether ...

    Authors: Gloria Benson, Andrea Hildebrandt, Catharina Lange, Claudia Schwarz, Theresa Köbe, Werner Sommer, Agnes Flöel and Miranka Wirth

    Citation: Alzheimer's Research & Therapy 2018 10:109

    Content type: Research

    Published on:

  19. Neurofibrillary pathology composed of tau protein is closely correlated with severity and phenotype of cognitive impairment in patients with Alzheimer’s disease and non-Alzheimer’s tauopathies. Targeting patho...

    Authors: Petr Novak, Reinhold Schmidt, Eva Kontsekova, Branislav Kovacech, Tomas Smolek, Stanislav Katina, Lubica Fialova, Michal Prcina, Vojtech Parrak, Peter Dal-Bianco, Martin Brunner, Wolfgang Staffen, Michael Rainer, Matej Ondrus, Stefan Ropele, Miroslav Smisek…

    Citation: Alzheimer's Research & Therapy 2018 10:108

    Content type: Research

    Published on:

  20. PQ912 is an inhibitor of the glutaminyl cyclase enzyme that plays a central role in the formation of synaptotoxic pyroglutamate-A-beta oligomers. We report on the first clinical study with PQ912 in subjects wi...

    Authors: Philip Scheltens, Merja Hallikainen, Timo Grimmer, Thomas Duning, Alida A Gouw, Charlotte E Teunissen, Alle Meije Wink, Paul Maruff, John Harrison, Caroline M van Baal, Suzanne Bruins, Inge Lues and Niels D Prins

    Citation: Alzheimer's Research & Therapy 2018 10:107

    Content type: Research

    Published on:

  21. The typical familial form of Alzheimer’s disease (FAD) accounts for about 5% of total Alzheimer’s disease (AD) cases. Presenilins (PSEN1 and PSEN2) and amyloid-β (A4) precursor protein (APP) genes carry all repor...

    Authors: Lara Paracchini, Luca Beltrame, Lucia Boeri, Federica Fusco, Paolo Caffarra, Sergio Marchini, Diego Albani and Gianluigi Forloni

    Citation: Alzheimer's Research & Therapy 2018 10:106

    Content type: Research

    Published on:

  22. Translational research in Alzheimer’s disease (AD) pathology provides evidence that accumulation of amyloid-β and hyperphosphorylated tau, neuropathological hallmarks of AD, is associated with complex disturba...

    Authors: Milan Stoiljkovic, Craig Kelley, Tamas L. Horvath and Mihály Hajós

    Citation: Alzheimer's Research & Therapy 2018 10:105

    Content type: Research

    Published on:

  24. The protective effect of education has been well established in Alzheimer’s disease, whereas its role in patients with isolated cerebrovascular diseases remains unclear. We examined the correlation of educatio...

    Authors: Na-Yeon Jung, Hanna Cho, Yeo Jin Kim, Hee Jin Kim, Jong Min Lee, Seongbeom Park, Sung Tae Kim, Eun-Joo Kim, Jae Seung Kim, Seung Hwan Moon, Jae-Hong Lee, Michael Ewers, Duk L Na and Sang Won Seo

    Citation: Alzheimer's Research & Therapy 2018 10:103

    Content type: Research

    Published on:

  25. There are currently no treatments for empathy deficits in neuropsychiatric disorders. Acute administration of the hormone oxytocin has been associated with symptomatic improvements across animal models and sev...

    Authors: Elizabeth Finger, Scott Berry, Jeffrey Cummings, Kristy Coleman, Robin Hsiung, Howard H. Feldman and Adam Boxer

    Citation: Alzheimer's Research & Therapy 2018 10:102

    Content type: Research

    Published on:

  27. With the shift of research focus towards the pre-dementia stage of Alzheimer’s disease (AD), there is an urgent need for reliable, non-invasive biomarkers to predict amyloid pathology. The aim of this study wa...

    Authors: Mara ten Kate, Alberto Redolfi, Enrico Peira, Isabelle Bos, Stephanie J. Vos, Rik Vandenberghe, Silvy Gabel, Jolien Schaeverbeke, Philip Scheltens, Olivier Blin, Jill C. Richardson, Regis Bordet, Anders Wallin, Carl Eckerstrom, José Luis Molinuevo, Sebastiaan Engelborghs…

    Citation: Alzheimer's Research & Therapy 2018 10:100

    Content type: Research

    Published on:

  28. Following publication of the original article [1], the author reported errors in the formatting of the table. The details of the errors are as follows:

    Authors: Susanne Ostrowitzki, Robert A. Lasser, Ernest Dorflinger, Philip Scheltens, Frederik Barkhof, Tania Nikolcheva, Elizabeth Ashford, Sylvie Retout, Carsten Hofmann, Paul Delmar, Gregory Klein, Mirjana Andjelkovic, Bruno Dubois, Mercè Boada, Kaj Blennow, Luca Santarelli…

    Citation: Alzheimer's Research & Therapy 2018 10:99

    Content type: Correction

    Published on:

    The original article was published in Alzheimer's Research & Therapy 2017 9:95

  29. Alzheimer’s disease (AD) is a complex neurodegenerative disorder characterized by neuropathologic changes involving beta-amyloid (Aβ), tau, neuronal loss, and other associated biological events. While levels o...

    Authors: Umesh Gangishetti, J. Christina Howell, Richard J. Perrin, Natalia Louneva, Kelly D. Watts, Alexander Kollhoff, Murray Grossman, David A. Wolk, Leslie M. Shaw, John C. Morris, John Q. Trojanowski, Anne M. Fagan, Steven E. Arnold and William T. Hu

    Citation: Alzheimer's Research & Therapy 2018 10:98

    Content type: Research

    Published on:

  30. Age is the cardinal risk factor for Alzheimer’s disease (AD), and white matter hyperintensities (WMH), which are more prevalent with increasing age, may contribute to AD. Higher cardiorespiratory fitness (CRF)...

    Authors: Clayton J. Vesperman, Vincent Pozorski, Ryan J. Dougherty, Lena L. Law, Elizabeth Boots, Jennifer M. Oh, Catherine L. Gallagher, Cynthia M. Carlsson, Howard A. Rowley, Yue Ma, Barbara B. Bendlin, Sanjay Asthana, Mark A. Sager, Bruce P. Hermann, Sterling C. Johnson, Dane B. Cook…

    Citation: Alzheimer's Research & Therapy 2018 10:97

    Content type: Research

    Published on:

  31. We investigated the effect of crenezumab, a humanized anti-amyloid-beta (Aβ) immunoglobulin (Ig)G4 monoclonal antibody, on biomarkers of amyloid pathology, neurodegeneration, and disease progression in patient...

    Authors: Stephen Salloway, Lee A. Honigberg, William Cho, Michael Ward, Michel Friesenhahn, Flavia Brunstein, Angelica Quartino, David Clayton, Deborah Mortensen, Tobias Bittner, Carole Ho, Christina Rabe, Stephen P. Schauer, Kristin R. Wildsmith, Reina N. Fuji, Shehnaaz Suliman…

    Citation: Alzheimer's Research & Therapy 2018 10:96

    Content type: Research

    Published on:

  32. Alzheimer’s disease (AD) is a progressive neurodegenerative disorder with a high prevalence among the elderly and a huge personal and societal impact. Recent epidemiological studies have indicated that the inc...

    Authors: Sylvie L. Lesuis, Lianne Hoeijmakers, Aniko Korosi, Susanne R. de Rooij, Dick F. Swaab, Helmut W. Kessels, Paul J. Lucassen and Harm J. Krugers

    Citation: Alzheimer's Research & Therapy 2018 10:95

    Content type: Research

    Published on:

  33. Cholinergic dysfunction is a key abnormality in Alzheimer disease (AD) that can be detected in vivo with transcranial magnetic stimulation (TMS) protocols. Although TMS has clearly demonstrated analytical vali...

    Authors: Alberto Benussi, Antonella Alberici, Clarissa Ferrari, Valentina Cantoni, Valentina Dell’Era, Rosanna Turrone, Maria Sofia Cotelli, Giuliano Binetti, Barbara Paghera, Giacomo Koch, Alessandro Padovani and Barbara Borroni

    Citation: Alzheimer's Research & Therapy 2018 10:94

    Content type: Research

    Published on:

  34. The principal aim of this study was to demonstrate the gender-specific cognitive patterns among middle-aged and elderly Chinese adults, investigate the risk factors on global and domain-specific cognitive perf...

    Authors: Yu An, Lingli Feng, Xiaona Zhang, Ying Wang, Yushan Wang, Lingwei Tao, Yanhui Lu, Zhongsheng Qin and Rong Xiao

    Citation: Alzheimer's Research & Therapy 2018 10:93

    Content type: Research

    Published on:

  35. Gender distribution varies across neurodegenerative disorders, with, traditionally, a higher female frequency reported in Alzheimer’s disease (AD) and a higher male frequency in Parkinson’s disease (PD). Confl...

    Authors: A. Mouton, F. Blanc, A. Gros, V. Manera, R. Fabre, E. Sauleau, I. Gomez-Luporsi, K. Tifratene, L. Friedman, S. Thümmler, C. Pradier, P. H. Robert and R. David

    Citation: Alzheimer's Research & Therapy 2018 10:92

    Content type: Research

    Published on:

  36. Brain reserve is a concept introduced to explain why Alzheimer’s disease (AD) patients with a greater brain volume prior to onset of pathology generally have better clinical outcomes. In this review, we provid...

    Authors: Anna Catharina van Loenhoud, Colin Groot, Jacob William Vogel, Wiesje Maria van der Flier and Rik Ossenkoppele

    Citation: Alzheimer's Research & Therapy 2018 10:91

    Content type: Review

    Published on:

  37. Cognitive composite scores are used as the primary outcome measures for Alzheimer’s disease (AD) prevention trials; however, the extent to which these composite measures correlate with AD pathology has not bee...

    Authors: Michael Malek-Ahmadi, Kewei Chen, Sylvia E. Perez, Anna He and Elliott J. Mufson

    Citation: Alzheimer's Research & Therapy 2018 10:90

    Content type: Research

    Published on:

  38. Interindividual differences in cognitive reserve (CR) are associated with complex and dynamic clinical phenotypes observed in cognitive impairment and dementia. We tested whether (1) CR early in life (E-CR; me...

    Authors: Shraddha Sapkota, Joel Ramirez, Donald T. Stuss, Mario Masellis and Sandra E. Black

    Citation: Alzheimer's Research & Therapy 2018 10:89

    Content type: Research

    Published on:

  39. Amyloid-beta (Aβ) has a dose-response relationship with cognition in healthy adults. Additionally, the levels of functional connectivity within and between brain networks have been associated with cognitive pe...

    Authors: Roy W. E. Van Hooren, Joost M. Riphagen and Heidi I. L. Jacobs

    Citation: Alzheimer's Research & Therapy 2018 10:88

    Content type: Research

    Published on:

  40. In this study, we tested to which extent possible between-center differences in standardized operating procedures (SOPs) for biobanking of cerebrospinal fluid (CSF) samples influence the homogeneity of the res...

    Authors: Piotr Lewczuk, Amélie Gaignaux, Olga Kofanova, Natalia Ermann, Fay Betsou, Sebastian Brandner, Barbara Mroczko, Kaj Blennow, Dominik Strapagiel, Silvia Paciotti, Jonathan Vogelgsang, Michael H. Roehrl, Sandra Mendoza, Johannes Kornhuber and Charlotte Teunissen

    Citation: Alzheimer's Research & Therapy 2018 10:87

    Content type: Research

    Published on:

  41. A relationship quantitative trait locus exists when the correlation between multiple traits varies by genotype for that locus. Relationship quantitative trait loci (rQTL) are often involved in gene-by-gene (G×...

    Authors: Taylor J. Maxwell, Chris Corcoran, Jorge L. del-Aguila, John P. Budde, Yuetiva Deming, Carlos Cruchaga, Alison M. Goate and John S. K. Kauwe

    Citation: Alzheimer's Research & Therapy 2018 10:86

    Content type: Research

    Published on:

  42. β-Secretase enzyme (BACE) inhibition has been proposed as a priority treatment mechanism for Alzheimer’s disease (AD), but treatment initiation may need to be very early. We present proof of mechanism of atabe...

    Authors: Maarten Timmers, Johannes Rolf Streffer, Alberto Russu, Yushin Tominaga, Hiroko Shimizu, Ayako Shiraishi, Kanaka Tatikola, Pascale Smekens, Anne Börjesson-Hanson, Niels Andreasen, Jorge Matias-Guiu, Miquel Baquero, Mercè Boada, Ina Tesseur, Luc Tritsmans, Luc Van Nueten…

    Citation: Alzheimer's Research & Therapy 2018 10:85

    Content type: Research

    Published on:

  43. Recently, the field of gene-gene or gene-environment interaction research appears to have gained growing interest, although it is seldom investigated in Alzheimer’s disease (AD). Hence, the current study aims ...

    Authors: Dahyun Yi, Younghwa Lee, Min Soo Byun, Jun Ho Lee, Kang Ko, Bo Kyung Sohn, Young Min Choe, Hyo Jung Choi, Hyewon Baek, Chul-Ho Sohn, Yu Kyeong Kim and Dong Young Lee

    Citation: Alzheimer's Research & Therapy 2018 10:84

    Content type: Research

    Published on:

  44. Little is known about the consequences of apathy in dementia with Lewy bodies (DLB), because previous research on apathy in dementia focused mainly on Alzheimer’s disease (AD).

    Authors: Monica H. Breitve, Kolbjørn Brønnick, Luiza J. Chwiszczuk, Minna J. Hynninen, Dag Aarsland and Arvid Rongve

    Citation: Alzheimer's Research & Therapy 2018 10:83

    Content type: Research

    Published on:

  45. Patients with amnestic mild cognitive impairment (aMCI) and Alzheimer’s disease (AD) show functional and structural connectivity alterations in the default mode network (DMN) while cerebrovascular disease (CeV...

    Authors: Ashwati Vipin, Yng Miin Loke, Siwei Liu, Saima Hilal, Hee Youn Shim, Xin Xu, Boon Yeow Tan, Narayanaswamy Venketasubramanian, Christopher Li-Hsian Chen and Juan Zhou

    Citation: Alzheimer's Research & Therapy 2018 10:82

    Content type: Research

    Published on:

  46. The immune system plays a major role in the pathogenesis of age-related dementia, including Alzheimer’s disease (AD). An insight into age-associated changes in the immune response to amyloid-beta (Aβ) in indiv...

    Authors: Sudhanshu Agrawal, Edsel M. Abud, Shikha Snigdha and Anshu Agrawal

    Citation: Alzheimer's Research & Therapy 2018 10:81

    Content type: Research

    Published on:

  47. There is accumulating evidence that synaptic loss precedes neuronal loss and correlates best with impaired memory formation in Alzheimer’s disease (AD). Cerebrospinal fluid (CSF) synaptosomal-associated protei...

    Authors: Hua Zhang, Joseph Therriault, Min Su Kang, Kok Pin Ng, Tharick A. Pascoal, Pedro Rosa-Neto and Serge Gauthier

    Citation: Alzheimer's Research & Therapy 2018 10:80

    Content type: Research

    Published on:

  48. Reliable biomarkers of frontotemporal dementia (FTD) are currently lacking. FTD may be associated with chronic immune dysfunction, microglial activation and raised inflammatory markers, particularly in progran...

    Authors: Ione O. C. Woollacott, Jennifer M. Nicholas, Amanda Heslegrave, Carolin Heller, Martha S. Foiani, Katrina M. Dick, Lucy L. Russell, Ross W. Paterson, Ashvini Keshavan, Nick C. Fox, Jason D. Warren, Jonathan M. Schott, Henrik Zetterberg and Jonathan D. Rohrer

    Citation: Alzheimer's Research & Therapy 2018 10:79

    Content type: Research

    Published on:

  49. The concept of dependence has been proposed as a unified representation of disease severity to quantify and stage disease progression in a manner more informative to patients, caregivers, and healthcare provid...

    Authors: Carolyn W. Zhu, Bote Gosse Bruinsma and Yaakov Stern

    Citation: Alzheimer's Research & Therapy 2018 10:78

    Content type: Review

    Published on:

  50. We aimed to describe the Subjective Cognitive Impairment Cohort (SCIENCe) study design, to cross-sectionally describe participant characteristics, and to evaluate the SCD-plus criteria.

    Authors: Rosalinde E. R. Slot, Sander C. J. Verfaillie, Jozefien M. Overbeek, Tessa Timmers, Linda M. P. Wesselman, Charlotte E. Teunissen, Annemiek Dols, Femke H. Bouwman, Niels D. Prins, Frederik Barkhof, Adriaan A. Lammertsma, Bart N. M. Van Berckel, Philip Scheltens, Sietske A. M. Sikkes and Wiesje M. Van der Flier

    Citation: Alzheimer's Research & Therapy 2018 10:76

    Content type: Research

    Published on:

Submit manuscript

Follow

  • ISSN: 1758-9193 (electronic)

Advertisement

Alzheimer's Research & Therapy

ISSN: 1758-9193